[go: up one dir, main page]

BR0213162A - Methods for the prevention and treatment of bone loss with steroid compounds. - Google Patents

Methods for the prevention and treatment of bone loss with steroid compounds.

Info

Publication number
BR0213162A
BR0213162A BR0213162-5A BR0213162A BR0213162A BR 0213162 A BR0213162 A BR 0213162A BR 0213162 A BR0213162 A BR 0213162A BR 0213162 A BR0213162 A BR 0213162A
Authority
BR
Brazil
Prior art keywords
prevention
treatment
methods
bone loss
steroid compounds
Prior art date
Application number
BR0213162-5A
Other languages
Portuguese (pt)
Inventor
Enrico Di Salle
Giorgio Massimini
Colin Lowery
Paul Edward Goss
Original Assignee
Pharmacia Italia Spa
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa, Upjohn Co filed Critical Pharmacia Italia Spa
Publication of BR0213162A publication Critical patent/BR0213162A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODOS PARA PREVENçãO E TRATAMENTO DA PERDA óSSEA COM COMPOSTOS ESTERóIDES". A presente invenção refere-se a um método de prevenção e tratamento de distúrbios anormais metabólicos ósseos em uma mulher em atividade de pós-menopausa ou ovariectomizada, o qual compreende a administração à dita mulher de uma quantidade terapeuticamente eficaz de exemestano ou 17-hidro-exemestano, individualmente ou em combinação com agentes terapêuticos adicionais."METHODS FOR PREVENTION AND TREATMENT OF BONE LOSS WITH STEROID COMPOUNDS". The present invention relates to a method of preventing and treating abnormal bone metabolic disorders in a postmenopausal or ovariectomized woman, which comprises administering to said woman a therapeutically effective amount of exemestane or 17-hydroxydehyde. individually, or in combination with additional therapeutic agents.

BR0213162-5A 2001-10-10 2002-09-30 Methods for the prevention and treatment of bone loss with steroid compounds. BR0213162A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32820901P 2001-10-10 2001-10-10
PCT/EP2002/011123 WO2003032961A2 (en) 2001-10-10 2002-09-30 Methods for preventing and treating bone loss with steroid compounds

Publications (1)

Publication Number Publication Date
BR0213162A true BR0213162A (en) 2004-09-14

Family

ID=23279989

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213162-5A BR0213162A (en) 2001-10-10 2002-09-30 Methods for the prevention and treatment of bone loss with steroid compounds.

Country Status (12)

Country Link
EP (1) EP1435967A2 (en)
JP (1) JP2005508958A (en)
KR (1) KR20050032507A (en)
CN (1) CN1713915A (en)
BR (1) BR0213162A (en)
CA (1) CA2463142A1 (en)
IL (1) IL161162A0 (en)
MX (1) MXPA04003405A (en)
NZ (1) NZ532064A (en)
PL (1) PL370080A1 (en)
WO (1) WO2003032961A2 (en)
ZA (1) ZA200402734B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
WO2005027916A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors
SG110107A1 (en) 2003-09-24 2005-04-28 Bioxell Spa Compound and use in treatment
WO2006114702A2 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
HUE033581T2 (en) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
ES2899860T3 (en) 2013-09-24 2022-03-15 Fujifilm Corp Novel nitrogen-containing compound or salt thereof, or metal complex thereof
RU2729518C2 (en) 2015-12-30 2020-08-07 Сент-Луис Юниверсити Meta-azacyclic aminobenzoic acid derivatives as pan-integrin antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8721384D0 (en) * 1987-09-11 1987-10-21 Erba Farmitalia 17-substituted andro-sta-1 4-dien-3-one derivatives
GB2294879A (en) * 1994-10-19 1996-05-15 Merck & Co Inc Cylcooxygenase-2 Inhibitors
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
ID28460A (en) * 1998-07-08 2001-05-24 Lipogenics Inc COMPOSITION AND METHODS FOR TREATMENT AND PREVENTION OF BONE DISEASE USING TOCOTRIENOL
BR0013272B1 (en) * 1999-08-13 2013-10-15 Use of a steroidal aromatase inhibitor

Also Published As

Publication number Publication date
CN1713915A (en) 2005-12-28
PL370080A1 (en) 2005-05-16
NZ532064A (en) 2006-04-28
CA2463142A1 (en) 2003-04-24
EP1435967A2 (en) 2004-07-14
WO2003032961A3 (en) 2003-09-04
KR20050032507A (en) 2005-04-07
WO2003032961A2 (en) 2003-04-24
IL161162A0 (en) 2004-08-31
ZA200402734B (en) 2005-01-13
MXPA04003405A (en) 2004-06-18
JP2005508958A (en) 2005-04-07

Similar Documents

Publication Publication Date Title
BR9813524A (en) Processes for treating toxicities associated with administering a therapeutic agent to a mammal, for treating toxicities associated with a mammal's exposure to radiation therapy, for treating neuro- or nephrodisturbs in a human, and for treating disorders and clinical symptoms associated with type i or type ii diabetes in a human
BR0013122A (en) Cyclobenzaprine for treatment of generalized anxiety disorder and cyclobenzaprine compositions
BR0211364A (en) Pharmaceutical composition for treating diseases associated with reduction in bone mass comprising ep4 agonist as active component
BR0009647A (en) Docetaxel in combination with rhumab her2 for the treatment of cancers
BR0206639A (en) Sterol Absorption Inhibitor (s) Combinations With Blood Modifier (s) For Treatment Of Vascular Conditions
BR0318269A (en) compositions, targets, methods and devices for the therapy of ocular and periocular disorders
BR0211062A (en) Combinations for the treatment of inflammatory disorders
BR9712824A (en) Ophthalmic composition of neurotrophic factor, treatment agent for functional optic nerve disorder and method for treating functional optic nerve disorder
BR9812134A (en) Pharmaceutical composition for the treatment of dysmenorrhea and premature birth
BRPI0417006A (en) local intraosseous administration of bone forming agents and anti-resorptive agents and devices therefor
BR0309623A (en) Regulating Agents. inhibit or modulate connective tissue growth factor (ctgf) activity and / or expression as a sole means of decreasing intraocular pressure and treating glaucomatous retinopathies / optic neuropathies
BR0317747A (en) Method of concomitant therapeutic treatment of an individual, pharmaceutical composition, kit, use of a first agent and a second agent, and methods of preventing or treating amyloid-b-related disease, alzheimer's disease and mild cognitive impairment
BR0015974A (en) Use of levetiracetam, pharmaceutical composition, use of a pharmaceutical composition and methods to treat a patient administered with an amount of at least one compound and a disease and to selectively potentiate the therapeutic effect of a compound
GB0108592D0 (en) Therapeutic agents
BR9814923A (en) Method for treating alzheimer's disease
BRPI0512220A (en) method for treating, preventing or ameliorating a disease or disorder; pharmaceutical composition; process for the preparation of a compound; and use of a compound
BRPI0512213A (en) method for treating, preventing or ameliorating a disease or disorder; pharmaceutical composition; process for the preparation of a compound; and use of a compound
MXPA03010843A (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease.
BRPI0411295A (en) compounds and their use in therapy
PL1703902T3 (en) Memantine for the treatment of mild-to-moderate alzheimer's disease
BR0014312A (en) Combination of loteprednol and antihistamines
BR9914419A (en) Perception improvement therapy
BR0315573A (en) Method for treating, preventing, controlling and / or modifying pain in a patient and pharmaceutical composition.
BRPI0408491A (en) treatment of alzheimer's disease
BR0200246A (en) Combination treatment for depression

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.